Commission and EIB provide CureVac with a €75 million financing for vaccine development and expansion of manufacturing

vaccinations CDC

(CDC, Unsplash)

This article is brought to you in association with the European Commission.


  • European Investment Bank and CureVac sign €75 million loan agreement for the development and large-scale production of vaccines, including CureVac’s vaccine candidate against SARS-CoV-2
  • The EIB loan will support CureVac’s activities to complete its new messenger ribonucleic acid (mRNA) production facility in Tübingen, Germany
  • The transaction is financed under the Infectious Diseases Finance Facility of Horizon 2020, the EU research and innovation programme for 2014-2020

The European Investment Bank (EIB) and CureVac, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimised mRNA, entered into a €75 million loan agreement to support the Company’s ongoing development of vaccines against infectious diseases, including its vaccine candidate CVnCoV aimed at preventing SARS-CoV-2 infections. In addition, the loan will support the Company’s efforts to expand its existing Good Manufacturing Practice (GMP) certified production capabilities and accelerate the completion of its fourth production site in Tübingen, Germany. The EIB financing will be provided in three €25 million tranches upon completion of pre-defined milestones.

Mariya Gabriel, Commissioner for Innovation, Research, Culture, Education and Youth, said: “The coronavirus will be with us, as long as we do not have a vaccine against it. This is why our work on this front, together with international actors, is so crucial. Recently we have presented our vaccines strategy to accelerate the development, manufacturing and deployment of vaccines against the novel coronavirus. And since the beginning of the pandemic, we increased the funding for the Infectious Diseases Finance Facility by €400 million to allow the EIB to process a higher volume of projects addressing this disease. With our support to CureVac we accelerate our efforts to find safe and effective solutions for everyone in Europe and globally.”

It does not need a pandemic to prove that new vaccines can be breakthroughs for public health,” said Ambroise Fayolle, EIB Vice-President in charge of innovation and health. “But in times like ours it becomes clear just how important they are to keep societies running globally. In fact, the only way to end the dramatic situation the world is facing since the outbreak of the COVID-19 pandemic would be a safe and effective vaccine. Thanks to our cooperation with the European Commission, we can finance more and more innovative biotech and medtech companies, such as CureVac, in their research and development of vaccines, therapeutics and diagnostics solutions. This is an added value of Europe, and the EIB does everything it can to maximise this value for the sake of people.”

Pierre Kemula, Chief Financial Officer of CureVac, added: “We are very pleased with the EIB financing. It allows us to further invest in our mRNA technology platform to fight life-threatening diseases. We are working intensively to develop a safe and effective low dose mRNA vaccine against SARS-CoV-2 and started a Phase 1 clinical trial of CVnCoV in June. We are looking forward to expediting the completion of our industrial-scale production site to provide critically needed supply of innovative mRNA-based vaccines.”

About CureVac’s mRNA technology platform

CureVac’s mRNA technology platform has shown potential in the clinical development and production of mRNA based vaccines and therapeutics. The Company’s proprietary RNAoptimizer® platform aims to optimize the properties of mRNA medicines based on its three core pillars: protein design, mRNA optimization and mRNA delivery. The technology can be tailored to induce varying degrees of immune responses against specific protein antigens of choice, potentially providing potent prophylactic vaccines for the prevention of infectious diseases at a low dose, such as Rabies, as well as immunotherapies for the treatment of cancer. The technology can also be adapted to avoid immune activation for purposes of protein therapy and antibodies, thereby providing potential new therapeutic modalities for patients suffering from a vast range of diseases.

The Infectious Diseases Finance Facility (IDFF) of the EU’s Horizon 2020 programme backs the loan to CureVac. The IDFF is an example of successful collaboration between the European Commission and the EIB in the face of a health crisis. Through the IDFF, the EIB has supported 13 companies with total lending of €316 million for developing cures, vaccines and diagnostics against various infectious diseases, most prominently the coronavirus.

 

Background

The European Investment Bank is the long-term lending institution of the European Union owned by its Member States. It makes long-term finance available for sound investments in order to contribute towards EU policy goals. The EIB also supports investments outside the EU.

The InnovFin Infectious Diseases Finance Facility (IDFF) is a financial product dedicated to support the fight against infectious diseases. The joint European Commission and EIB Group initiative falls under Horizon2020, the 2014-2020 EU research and innovation programme. IDFF enables the EIB to provide between €7.5 million and €75 million of funding to innovative players active in developing vaccines, drugs, medical and diagnostic devices and research infrastructure for combatting infectious diseases. The loans finance clinical trials, market access, and the development of prototypes or industrial roll out of novel equipment, pre-clinical R&D and working capital needs. The IDFF has been reinforced by €400 million to better tackle the outbreak of COVID-19.

CureVac is a leading clinical stage biotechnology company in the field of messenger RNA (mRNA) technology with 20 years of expertise in developing and optimizing this versatile molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.

the sting Milestones

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

MEPs demand an end to migrant deaths across the Mediterranean Sea

Air pollution: How to end the deaths of 7 million people per year

This project is using AI and drones to track and protect great white sharks

Main results of EU-Japan summit: Tokyo, 17/07/2018

We don’t know how autonomous vehicles will depreciate – and that’s a problem

ACP-EU Post-Cotonou: A Joint Parliamentary Assembly is non-negotiable

How Africa’s women can drive the 4IR forward

Employment: Commission proposes €1.6 million from Globalisation Adjustment Fund to help 400 workers made redundant in Carrefour Belgique

Achieving targets on energy helps meet other Global Goals, UN forum told

We can build an inclusive workplace, and it starts with empathy

Macron plans for Europe, Brexit and banks but vague on France

How cities are failing to be inclusive – and what they can do about it

‘Never give up’: UN chief urges all who serve, marking UN Day

The banks first to benefit from the new euro trillion ECB plans to print

GSMA Mobile 360 – Africa on 16-18 July 2019, in association with The European Sting

More funds needed to counter ‘persistent and multi-faceted humanitarian problems’ in Ethiopia

The EU wants to create 10 million smart lampposts

School closures triple in Central and Western Africa as education comes under fire

COP22 addresses a strong global pledge to effectively implement the Paris Agreement

Common charger: a long-awaited proposal requested by Parliament

UK must end ‘unlawful’ administration of Chagos Archipelago ‘as rapidly as possible,’ top UN court rules

This tiny new grain could save the planet

The challenge of palliative care in universal health coverage

UN chief saddened at news of death of former US President George H.W. Bush

Financial system risk is elevated and global standards are essential in managing cross-border infrastructure investment

This Dutch floating village could help tackle city-density and sea-level challenges

New rules make household appliances more sustainable

UN ‘regrets’ new US position on legality of Israeli settlements

Maros Sefcovic Canete European Commission Energy

Better late than never? Commission runs now to fight energy dependency on Russia with the sustainable energy security package

Stuck at sea: How to save the world’s seafarers and the supply systems they support

State aid: Commission approves Luxembourg guarantee measure to further support economy in coronavirus outbreak

FROM THE FIELD: Conversations about Conservation

Reform of road use charges to spur cleaner transport and ensure fairness

General Assembly officially adopts roadmap for migrants to improve safety, ease suffering

Mozambique cyclones a ‘wake-up call’ to boost resistance: UN weather agency

Global leaders and companies pledge to reduce the gender pay gap by 2030

What you need to know about the Sustainable Development Impact Summit

Support ‘winds of change’ in DR Congo to consolidate positive developments, urges UN mission chief

Coldplay stop touring to save the world: is pop music going sustainable?

EU finally agreed to cut roaming charges in 2017 but criticism is always there

Europe should make voice ‘more heard’ in today’s ‘dangerous world,’ says UN chief

COP21 Breaking News_03 December: There is a new draft agreement on the negotiating table

Turkey caught in a vicious Syrian circle bringing terror and war at home

How our Europe will regain its strength: op-ed by Ursula von der Leyen, President of the European Commission

The European Sting @ European Business Summit 2014 – the preview

Women in Leadership, a Cognitive and Psychological Approach

How start-ups will lead India through the Fourth Industrial Revolution

NextGenerationEU: European Commission endorses Romania’s €29.2 billion recovery and resilience plan

The new era of Matriarchy?

COP21 Breaking News: Paris Pact on Water and Climate Change Adaptation Announced

Blockchain is becoming key for global trade – but is that a gift for hackers?

Powering through the pandemic

Bigotry ‘moving at lightning speed’ Guterres warns, as UN marks the Holocaust

Who the US and China have trade disputes with

Is co-living an answer to the affordable housing crisis?

Mine ban agreement ‘has saved countless lives’, but ‘accelerated efforts’ needed to end scourge for good: Guterres

Wars have rules: 5 things the UN humanitarian chief wants countries to tackle so human suffering in conflict can be minimized

State aid: Commission approves French scheme deferring payment by airlines of certain taxes to mitigate economic impact of coronavirus outbreak

Coronavirus: Commission launches call for innovative response and recovery partnerships between EU regions

European Accessibility Act: Parliament and Council negotiators strike a deal

More Stings?

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: